In the AML-SG study, a randomized trial was conducted to evaluate GO in combination with intensive induction and consolidation therapy in NPM1-mutated AML, as the high CD33 expression in AML with mutated NPM1 provides a rationale for the evaluation of GO in this AML entity. The gene discussed is NPM1; the disease is acute myeloid leukemia.